Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Elevated Th17 cells associated with increased risk of critical COVID

In a recent article published in the European Journal of Internal Medicine, researchers in France indicated that T cell immune reaction correlates possibly with the chance of critical severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among hospitalized patients.

14 Jun 2022

SARS-CoV-2 BA.4/5 variants escape vaccine and BA.1 infection induced antibodies

In a recent work published in the Cell journal, investigators examined the severe acute respiratory syndrome coronavirus (SARS-CoV-2) Omicron BA.5/4 variants escape from neutralizing antibodies induced by SARS-CoV-2 vaccines and natural infection.

13 Jun 2022

Study reports robust immunity to SARS-CoV-2 including Omicron BA.1 for all three primary vaccines

In a recent study posted to the medRxiv* pre-print server, researchers in the United Kingdom investigated the effect of two Pfizer/BioNTech BNT162b2 vaccine doses or Oxford/AstraZeneca AZ1222 coronavirus disease 2019 (COVID-19) vaccination and a subsequent BNT162b2 booster dose in a cohort of healthcare workers (HCWs) over six to nine months.

10 Jun 2022

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID

In a recent study published in the Lancet, researchers evaluated the safety and efficacy of tixagevimab–cilgavimab, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody (mAb) combination in patients with mild to moderate coronavirus disease 2019 (COVID-19).

8 Jun 2022

NIH sponsors the trial of monoclonal antibody to prevent asthma exacerbations in urban youth

The National Institutes of Health has launched a clinical trial testing whether a monoclonal antibody, dupilumab, can reduce asthma attacks and improve lung function and asthma symptoms in children with poorly controlled allergic asthma who live in low-income urban neighborhoods.

2 Jun 2022

Prevalence of SARS-CoV-2 infection during Omicron BA.2/BA.2.12.1 surge in New York

Researchers surveyed a representative sample of the adult population of New York City, United States, to determine the prevalence of COVID-19.

30 May 2022

Researchers identify a human monoclonal antibody that could broadly neutralize several variants of SARS-CoV-2, SARS-CoV, and other coronaviruses

Researchers identified 10-40, a human monoclonal antibody with potent neutralizing activity against SARS-CoV, SARS-CoV-2, and related sarbecoviruses.

30 May 2022

The effectiveness of sotrovimab vs. molnupiravir in preventing severe COVID-19 outcomes in non-hospitalized high-risk COVID-19 adult patients

Researchers compared the efficacy of sotrovimab and molnupiravir in preventing severe COVID-19 outcomes among non-hospitalized and high-risk COVID-19 patients across England.

25 May 2022

The impact of SARS-CoV-2 nucleocapsid protein mutations on the performance of rapid antigen tests

The study findings showed that the rapid antigen tests with the DMS approach could accurately identify antibody escape mutations in the SARS-CoV-2 N protein.

24 May 2022

Study reports SARS-CoV-2 accessory proteins downregulate MHC-I expression using distinct mechanisms

Researchers observed SARS-CoV-2 downregulates the expression of MHC class I molecules.

23 May 2022

Exploring cross-neutralizing anti-SARS-CoV-2 antibody responses among the general population

Researchers performed a molecular analysis of cross-reactive antibodies targeted against the receptor-binding domain of SARS-CoV-2 strains among the general population.

20 May 2022

Two Rutgers engineers create analytical tool to accelerate the production of biologic drugs

Two Rutgers engineers specializing in the process of making drugs derived from living organisms have created an analytical tool they expect will accelerate the discovery and production of biologic drugs that are often at the cutting edge of biomedical research.

18 May 2022

First patient dosed in Phase 1 clinical trial evaluating the safety of CF33-hNIS against solid tumors

Imugene Limited, a clinical stage immuno-oncology company, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient was dosed in a Phase 1 clinical trial evaluating the safety of novel cancer-killing virus CF33-hNIS VAXINIA when used in people with advanced solid tumors.

18 May 2022

Discovery of a potent SARS-CoV-2 RBD specific human monoclonal antibody

A recent article posted to the bioRxiv* preprint server demonstrated structural underpinnings of the neutralization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants by 002-S21F2, an extensive SARS-CoV-2 neutralizing antibody.

18 May 2022

Researchers explore COVID-19 vaccination in immunocompromised individuals

A new study discusses the safety and efficacy of the COVID-19 vaccination and potential strategies to optimize protection in patients with impaired immunity.

17 May 2022

Neutralization of SARS-CoV-2 by plant-made neutralizing monoclonal antibodies

In a recent study published in the journal Vaccines, researchers developed plant-based monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

17 May 2022

Susceptibility of four SARS-CoV-2 Omicron sub-lineages to vaccines and monoclonal antibodies

Researchers demonstrated that four SARS-CoV-2 Omicron sub-lineages, BA.1, BA.1.1, BA.2, and BA.3, are resistant to current COVID-19 vaccines and antibody therapeutics to varying extents.

11 May 2022

Benefit from convalescent plasma shown in COVID outpatient trial

Researchers have conducted a double-blind, multicentre, randomized, controlled trial, which is known as Convalescent Plasma to Limit SARS-CoV-2 Associated Complications Study to evaluate if early COVID-19 plasma treatment could reduce disease progression and, thereby, reduce hospitalization rate.

9 May 2022

Study reveals underlying signaling pathway that results in pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the lungs, in which blood vessels are narrowed, blocked or destroyed, causing the heart to work harder and, in time, result in cardiac weakness and failure.

6 May 2022

Stem cell therapy prevents type 1 diabetes induced by anti-cancer drugs

Immune checkpoint inhibitors are widely used to treat a variety of cancers; however, one serious side effect is the onset of type 1 diabetes.

6 May 2022

Monoclonal Antibody News and Research

Further Reading

Elevated Th17 cells associated with increased risk of critical COVID

SARS-CoV-2 BA.4/5 variants escape vaccine and BA.1 infection induced antibodies

Study reports robust immunity to SARS-CoV-2 including Omicron BA.1 for all three primary vaccines

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID

NIH sponsors the trial of monoclonal antibody to prevent asthma exacerbations in urban youth

Prevalence of SARS-CoV-2 infection during Omicron BA.2/BA.2.12.1 surge in New York

Researchers identify a human monoclonal antibody that could broadly neutralize several variants of SARS-CoV-2, SARS-CoV, and other coronaviruses

The effectiveness of sotrovimab vs. molnupiravir in preventing severe COVID-19 outcomes in non-hospitalized high-risk COVID-19 adult patients

The impact of SARS-CoV-2 nucleocapsid protein mutations on the performance of rapid antigen tests

Study reports SARS-CoV-2 accessory proteins downregulate MHC-I expression using distinct mechanisms

Exploring cross-neutralizing anti-SARS-CoV-2 antibody responses among the general population

Two Rutgers engineers create analytical tool to accelerate the production of biologic drugs

First patient dosed in Phase 1 clinical trial evaluating the safety of CF33-hNIS against solid tumors

Discovery of a potent SARS-CoV-2 RBD specific human monoclonal antibody

Researchers explore COVID-19 vaccination in immunocompromised individuals

Neutralization of SARS-CoV-2 by plant-made neutralizing monoclonal antibodies

Susceptibility of four SARS-CoV-2 Omicron sub-lineages to vaccines and monoclonal antibodies

Benefit from convalescent plasma shown in COVID outpatient trial

Study reveals underlying signaling pathway that results in pulmonary arterial hypertension

Stem cell therapy prevents type 1 diabetes induced by anti-cancer drugs

Antibodies eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News